Ayala Pharmaceuticals Inc (fka ADXS)

[DewDiligence]

Delaying the length of time it takes for investors to find out the drug isn't efficacious?

A cynic might say that delaying the results from the first randomized controlled trial for as long as ADXS has done with AIM2CERV enables management to string investors along for several years while insiders benefit personally.

ADXS could have run its first phase-3 trial in the metastatic setting, where results would have been available much sooner than the results from AIM2CERV.

This is not a novel concept. There are certainly some biotech companies who have played such a game.